Last reviewed 2026-04-23 · How we verify

ITCZ-IV

ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Blastomycosis, Histoplasmosis.

At a glance

Mechanism of action

Itraconazole works by blocking a key enzyme in the fungal sterol synthesis pathway, leading to depletion of ergosterol and accumulation of toxic sterol precursors. This destabilizes the fungal cell membrane, causing cell death. The IV formulation allows systemic delivery for serious invasive fungal infections where oral bioavailability is inadequate.

Approved indications

• Invasive aspergillosis
• Blastomycosis
• Histoplasmosis
• Cryptococcosis

Common side effects

• Hypokalemia
• Elevated liver enzymes
• Renal impairment
• Infusion-related reactions
• Nausea

Key clinical trials

• A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.